目的 探讨盐酸川芎嗪注射液联合低分子量肝素钙注射液治疗早发型重度子痫前期的临床疗效。方法 选取2017年1月—2018年5月海南省第三人民医院收治的126例早发型重度子痫前期患者作为研究对象，采用随机数字表法将患者分为对照组和治疗组，每组各63例。对照组患者腹壁皮下注射低分子量肝素钙注射液，50～85 U/kg，1次/d。治疗组在对照组治疗的基础上静脉滴注盐酸川芎嗪注射液，2支加入5%葡萄糖注射液250 mL中，2～3 h滴完，1次/d。两组患者均连用5 d后休息2 d，每周重复1个疗程，终止妊娠前24 h停药。比较两组患者的平均动脉压、24 h尿蛋白定量、凝血功能指标、D-二聚体（D-D）水平、新生儿出生体质量、Apgar评分和死亡率。结果 治疗后，两组平均动脉压和24 h尿蛋白定量均显著下降，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组平均动脉压和24 h尿蛋白定量明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组纤维蛋白原（FIB）、D-D水平均明显下降，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组FIB、D-D明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组新生儿死亡率明显低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 盐酸川芎嗪注射液联合低分子量肝素钙注射液治疗早发型重度子痫前期可改善患者临床症状和血液高凝状态，降低新生儿死亡率，具有一定的临床推广应用价值。

Objective To investigate the efficacy of Ligustrazine Hydrochloride Injection combined with Low Molecular Weight Heparin Calcium Injection in treatment of early onset severe preeclampsia. Methods Patients (126 cases) with early onset severe preeclampsia in the Third People's Hospital of Hainan Province from January 2017 to May 2018 were randomly divided into control and treatment groups, and each group had 63 cases. Patients in the control group were subcutaneously injected with Low Molecular Weight Heparin Calcium Injection, 50-85 U/kg, once daily. Patients in the treatment group were iv administered with Ligustrazine Hydrochloride Injection on the basis of the control group, 2 bottles were added into 250 mL of 5% Glucose Injection, and dripped 2-3 h, once daily. Patients in two groups were treated for 5 d, and stopped it for 2 d, and repeated one course of treatment every week. The drug was discontinued 24 h before the termination of pregnancy. After treatment, the mean arterial pressure, 24 h urine protein, coagulation function indexes, D-D level, birth weight, Apgar score, and mortality in two groups were compared. Results After treatment, the mean arterial pressure and 24 h urine protein in two groups were significantly decreased, and there were differences in the same group (P<0.05). After treatment, the mean arterial pressure and 24 h urine protein in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of FIB and D-D in two groups were significantly decreased, and there were differences in the same group (P<0.05). After treatment, the FIB and D-D in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, neonatal mortality in the treatment group was significantly lower than that in the control group, and there were differences in the same group (P<0.05). Conclusion Ligustrazine Hydrochloride Injection combined with Low Molecular Weight Heparin Calcium Injection in treatment of early onset severe preeclampsia can improve clinical symptoms and blood hypercoagulability, and reduce neonatal mortality, which has a certain clinical application value.